Bita Nehoray
Overview
Explore the profile of Bita Nehoray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
420
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raz D, Nehoray B, Ceniceros A, Motarjem P, Landau S, Nelson R, et al.
Cancer
. 2025 Jan;
131(1):e35709.
PMID: 39748640
Background: The authors assessed the feasibility, acceptability, and impact on cancer worry of a cancer screening program using multicancer early detection (MCED) tests and whole-body magnetic resonance imaging (WBM) in...
2.
Chavarri-Guerra Y, Ferrigno-Guajardo A, Villarreal-Garza C, Martinez-Cannon B, Abugattas-Saba J, Fontaine A, et al.
JCO Glob Oncol
. 2024 Oct;
10:e2400097.
PMID: 39481075
Purpose: Women with pathogenic variants (PVs) in breast cancer (BC) and ovarian cancer (OC) associated genes are candidates for cancer risk-reducing strategies. Limited information is available regarding risk-reducing surgeries (RRS)...
3.
Capasso A, Nehoray B, Gorman N, Quinn E, Bucio D, Blazer K
J Genet Couns
. 2024 Mar;
34(1):e1887.
PMID: 38480478
As demand for genetic cancer risk assessment (GCRA) continues to increase, so does the sense of urgency to scale up efforts to triage patients, facilitate informed consent, and order genetic...
4.
Coudert M, Drouet Y, Delhomelle H, Svrcek M, Benusiglio P, Coulet F, et al.
J Med Genet
. 2022 Aug;
59(12):1189-1195.
PMID: 36038258
Background: Pathogenic variants (PV) of are found in families fulfilling criteria for hereditary diffuse gastric cancer (HDGC) but no risk estimates were available until now. The aim of this study...
5.
Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
Castillo D, Yuan T, Nehoray B, Cervantes A, Tsang K, Yang K, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Jun;
31(8):1621-1629.
PMID: 35654360
Background: Though germline TP53 pathogenic/likely pathogenic variants (PV) are associated with Li-Fraumeni syndrome, many detected by multigene panels represent aberrant clonal expansion (ACE), most due to clonal hematopoiesis (CH). Discerning...
6.
Nehoray B, Slavin T, Sun C, Hurley K, King E, Tsang K, et al.
J Genet Couns
. 2022 May;
31(5):1164-1172.
PMID: 35617031
Next-generation tumor tissue sequencing techniques may result in the detection of putative germline pathogenic variants (PVs), raising the possibility that germline cancer predisposition could be identified from archival medical tissue...
7.
Herzog J, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S, et al.
NPJ Breast Cancer
. 2021 Aug;
7(1):107.
PMID: 34413315
The prevalence and contribution of BRCA1/2 (BRCA) pathogenic variants (PVs) to the cancer burden in Latin America are not well understood. This study aims to address this disparity. BRCA analyses...
8.
Blazer K, Chavarri-Guerra Y, Garza C, Nehoray B, Mohar A, Daneri-Navarro A, et al.
JCO Glob Oncol
. 2021 Jun;
7:992-1002.
PMID: 34181458
Purpose: Genomic cancer risk assessment (GCRA) is standard-of-care practice that uses genomic tools to identify individuals with increased cancer risk, enabling screening for early detection and cancer prevention interventions. GCRA...
9.
Weitzel J, Kidd J, Bernhisel R, Shehayeb S, Frankel P, Blazer K, et al.
Breast Cancer Res Treat
. 2021 Apr;
188(3):759-768.
PMID: 33826040
Purpose: The prevalence, penetrance, and spectrum of pathogenic variants that predispose women to two or more breast cancers is largely unknown. Methods: We queried clinical and genetic data from women...
10.
Clark D, Michalski S, Tondon R, Nehoray B, Ebrahimzadeh J, Hughes S, et al.
Genet Med
. 2020 Feb;
22(5):840-846.
PMID: 32051609
Purpose: CTNNA1 is a potential diffuse gastric cancer risk gene, however CTNNA1 testing on multigene panel testing (MGPT) remains unstudied. Methods: De-identified data from 151,425 individuals who underwent CTNNA1 testing...